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Abstract
Aims Recent international heart failure (HF) guidelines recognize anaemia as an important comorbidity contributing to poor
outcomes in HF, based on data mainly from Western populations. We sought to determine the prevalence, clinical correlates,
and prognostic impact of anaemia in patients with HF with reduced ejection fraction across Asia.
Methods and results We prospectively studied 3886 Asian patients (60 ± 13 years, 21% women) with HF (ejection fraction
≤40%) from 11 regions in the Asian Sudden Cardiac Death in Heart Failure study. Anaemia was deﬁned as haemoglobin
<13 g/dL (men) and <12 g/dL (women). Ethnic groups included Chinese (33.0%), Indian (26.2%), Malay (15.1%),
Japanese/Korean (20.2%), and others (5.6%). Overall, anaemia was present in 41%, with a wide range across ethnicities
(33–54%). Indian ethnicity, older age, diabetes, and chronic kidney disease were independently associated with higher odds
of anaemia (all P < 0.001). Ethnicity modiﬁed the association of chronic kidney disease with anaemia (Pinteraction = 0.045), with
the highest adjusted odds among Japanese/Koreans [2.86; 95% conﬁdence interval (CI) 1.96–4.20]. Anaemic patients had
lower Kansas City Cardiomyopathy Questionnaire scores (P < 0.001) and higher risk of all-cause mortality and HF hospitaliza-
tion at 1 year (hazard ratio = 1.28, 95% CI 1.08–1.50) compared with non-anaemic patients. The prognostic impact of anaemia
was modiﬁed by ethnicity (Pinteraction = 0.02), with the greatest hazard ratio in Japanese/Koreans (1.82; 95% CI 1.14–2.91).
Conclusions Anaemia is present in a third to more than half of Asian patients with HF and adversely impacts quality of life
and survival. Ethnic differences exist wherein prevalence is highest among Indians, and survival is most severely impacted by
anaemia in Japanese/Koreans.
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Introduction
Recent international heart failure (HF) guidelines recognize
anaemia as an important comorbidity contributing to
symptomatology and poor outcomes in HF.1 The causes of
anaemia in HF are multifactorial, and its impact on quality of
life (QoL) and outcomes may vary by ethnic background. Prior
reports are mainly from Western populations, where the
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prevalence of anaemia in patients with heart failure with re-
duced ejection fraction has been reported to range between
16% and 34%, and anaemia has been shown to contribute in-
dependently to morbidity and mortality.2–13 Prevalence of
anaemia is higher in the general population of Asian com-
pared with Western countries and varies widely across
Asia.14 Yet in contrast to the wealth of data in Western pa-
tients, data on anaemia in Asian patients with HF are scarce
and limited to single country surveys.15,16 We therefore aimed
to determine the prevalence, clinical correlates, and impact of
anaemia on the QoL and outcomes among Asian patients with
HF in the multinational multi-ethnic Asian Sudden Cardiac
Death in Heart Failure (ASIAN-HF) registry.17,18
Methods
The ASIAN-HF registry17,18 is a prospective observational mul-
tinational registry of Asian patients >18 years of age with
symptomatic HF (at least one episode of decompensated HF
in the previous 6 months that resulted in a hospital admission
or was treated in an outpatient clinic) and left ventricular
ejection fraction (LVEF) ≤40% on baseline echocardiography,
from 46 medical centres across 11 Asian regions (China, Hong
Kong, India, Indonesia, Japan, Korea, Malaysia, Philippines,
Singapore, Taiwan, and Thailand). Those with severe valve
disease as the primary cause of HF, life-threatening comor-
bidity with life expectancy of <1 year, who were unable or
unwilling to give consent, or have concurrent participation
in a clinical therapeutic trial were excluded.17,18 Comprehen-
sive data collection at baseline included demographic charac-
teristics, clinical attributes, laboratory investigations, and
health-related QoL scores.
A total of 3886 out of 5276 patients enrolled in the study
had serum haemoglobin (Hb) levels recorded at baseline
and were included in the current analyses. Anaemia was
deﬁned according to World Health Organization (WHO)
criteria of Hb <13 g/dL for men and <12 g/dL for women.19
The estimated glomerular ﬁltration rate (eGFR) was
calculated using the modiﬁcation of diet in renal disease
formula. Chronic kidney disease (CKD) was deﬁned as
eGFR < 60 mL/min/1.73 m2.20
Self-reported ethnicity was classiﬁed as Chinese, Indian,
Malay, Japanese/Korean, and others. Other ethnicities
included Thai, Filipino, and indigenous South-east Asian
patients, which were grouped due to small numbers.
Geographic regions were categorized according to the United
Nations classiﬁcation as North-east Asia (South Korea, Japan,
Taiwan, Hong Kong, and China), South Asia (India), and
South-east Asia (Thailand, Malaysia, Philippines, Indonesia,
and Singapore). Regions were also classiﬁed according to
WHO income level groups as lower income (Indonesia,
Philippines, and India), middle income (China, Thailand, and
Malaysia), and higher income (Singapore, Hong Kong,
Taiwan, South Korea, and Japan) groups.
All patients were followed for 1 year for the primary
composite outcome of all-cause mortality and HF hospitaliza-
tions and the secondary outcome of all-cause mortality. An
independent outcomes committee adjudicated all outcome
events.
This study complied with the Declaration of Helsinki, and
all patients provided written informed consent. Ethics
approval was obtained from the relevant local human ethics
committees at all sites. Quintiles Outcomes, the contract
research organization appointed by the ASIAN-HF academic
Executive Committee, handled all registry operations and
data management.
Statistical analysis
Categorical variables are presented as numbers with percent-
ages. Continuous variables are presented as medians with in-
terquartile (IQR) ranges or as means ± standard deviation as
appropriate. Baseline characteristics of anaemic vs. non-
anaemic patients were compared using χ2 tests, Student’s t-
tests, or Wilcoxon rank-sum tests depending on the type
and distribution of variables.
Univariable logistic regression was ﬁrst performed on all
baseline variables for their association with anaemia. Vari-
ables that had P < 0.10 and clinically important variables
were then included in the ﬁnal multivariable model for anae-
mia. These included age, sex, ethnicity, income region, New
York Heart Association class, LVEF, HF aetiology, alcohol his-
tory, presence of peripheral oedema or elevated jugular ve-
nous pressure (JVP), body mass index, diastolic blood
pressure, use of diuretics, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers (ACEi/ARBs), or min-
eralocorticoid receptor antagonists (MRAs), presence of dia-
betes, or CKD. Interaction analysis was performed to assess
if the relationship between anaemia and clinically important
variables varied by ethnicity.
We depicted outcomes between anaemic and non-
anaemic patients using Kaplan–Meier curves and tested
differences in crude survival using the log-rank test. For
multivariable analyses, we performed Cox regression analy-
sis and validated the proportional hazards assumption using
Schoenfeld residuals. The Cox regression model was
adjusted for clinically meaningful covariates including age,
sex, ethnicity, regional income, education level, HF
aetiology, LVEF, alcohol, smoking history, use of MRAs,
ACEi/ARBs, beta-blockers and diuretics, and presence of
CKD, diabetes, atrial ﬁbrillation/ﬂutter, peripheral artery
disease, liver disease, stroke, chronic obstructive pulmonary
disease, and cancer. Interaction analysis was performed to
assess if the relationship between anaemia and the compos-
ite outcome was modiﬁed by ethnicity or clinically
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important variables such as diabetes and CKD. Similar
analyses were performed to study the associations between
Hb (modelled as quintiles) and the primary or secondary
outcomes.
The Kansas City Cardiomyopathy Questionnaire (KCCQ), a
23-item self-administered HF-speciﬁc questionnaire, was
used to examine patient-centred QoL. This instrument has
been widely used in recent international HF clinical trials
and has been validated in several languages.21,22 Non-
English speaking participants used certiﬁed versions of the
KCCQ translated into their native languages. Computed
KCCQ scores23 range from 0 to 100, with higher scores
representing better health-related QoL. KCCQ scores were
adjusted for the same clinically meaningful covariates as de-
scribed previously.
A value of P ≤ 0.05 was considered statistically signiﬁcant.
STATA (version 13) software was used to perform all analyses
(StataCorp LP, College station, Texas, USA).
Results
Baseline characteristics
Among 3886 Asian patients with HF (60 ± 13 years, 21%
women) and available Hb values, anaemia was present in
40% men and 45% women. Compared with non-anaemic pa-
tients, anaemic patients were older, more often female, with
worse New York Heart Association functional status, higher
prevalence of hypertension, diabetes, CKD, and peripheral
artery disease, and worse signs of congestion (peripheral
oedema and raised JVP) (Table 1). Furthermore, anaemic
patients were more often treated with diuretics but less of-
ten treated with evidence based therapy such as ACEi/ARBs,
beta-blockers, and MRAs, than non-anaemic patients (all
P < 0.02) (Table 1).
As shown in Supporting Information, Table S1, compared
with patients without Hb values, those with Hb values were
slightly older, more likely to be from high income regions,
and had a greater burden of comorbidities.
Association between anaemia and clinical
variables
The prevalence of anaemia varied among ethnicities and was
highest in Indians (54.4%), followed by Malays, Japanese/
Koreans, Chinese, and other ethnicities (Figure 1A–B). Indepen-
dent predictors of anaemia were older age [odds ratio
(OR) = 1.03, 95% conﬁdence interval (CI) 1.02–1.03], Indian eth-
nicity (OR = 3.00, 95% CI 2.17–4.17), LVEF (OR = 1.04, 95% CI
1.02–1.05), diuretic use (OR = 1.26, 95% CI 1.01–1.56), diabetes
(OR = 1.75, 95% CI 1.47–2.08), and CKD (OR = 1.71, 95% CI
1.44–2.03). In contrast, patients with a history of alcohol use
(OR = 0.75, 95% CI 0.62–0.90), higher body mass index
(OR = 0.96, 95% CI 0.94–0.98), higher diastolic blood pressure
(OR = 0.98, 95% CI 0.97–0.98), and receiving ACEi/ARBs
(OR = 0.67, 95% CI 0.55–0.81) were less likely to be anaemic.
Ethnicity modiﬁed the association between anaemia and CKD
(Pinteraction = 0.045), where the strongest independent associa-
tions between anaemia and CKD were observed in
Japanese/Korean (OR = 2.86, 95% CI 1.96–4.20) and other eth-
nicities (OR = 4.40, 95% CI 1.85–10.48); however, the CIs for the
latter were wide.
Quality of life of ASIAN-HF patients with anaemia
Importantly, anaemia adversely affected patients’ health-
related QoL (using the KCCQ), with adjusted KCCQ scores be-
ing signiﬁcantly lower in anaemic vs. non-anaemic patients
across most KCCQ domains (Table 1). In particular, physical
limitation, social limitation, and symptom frequency domains
were affected. Ethnicity did not modify the effect of anaemia
on KCCQ scores in this cohort.
Outcomes of ASIAN-HF patients with anaemia
A total of 767 (22.1%) patients experienced the primary
composite outcome of death or HF hospitalization at
1 year. Crude 1 year mortality was higher in anaemic vs.
non-anaemic patients [201 (14.1%) vs. 194 (9.6%),
P < 0.001]. Anaemia was associated with higher hazards
of the primary composite outcome [hazard ratio
(HR) = 1.28, 95% CI 1.08–1.50] (Table 2) and 1 year all-
cause mortality (HR = 1.39, 95% CI 1.10–1.75). A signiﬁ-
cant interaction was found between ethnicity and anaemia
on the primary composite outcome (Pinteraction = 0.023).
Here, we found that anaemia was associated with worse
outcomes in Japanese/Koreans patients (adjusted HR
1.82; 95% CI 1.14–2.91, P = 0.012) (Table 2). Despite the
higher prevalence of anaemia in Indians, the absence of
signiﬁcant association between anaemia and outcomes in
Indians was observed. Outcomes among Indian patients
were better compared with other ethnic groups (Table 2,
Figure 1C). Intriguingly, Indians with anaemia were found
to have the highest eGFR (63 [IQR 40, 86] mL/min/
1.73 m2) when compared with the other ethnicities
with anaemia (range: 43 [IQR 25, 58] to 53 [IQR 35,
74] mL/min/1.73 m2). Anaemic Indians were also signiﬁ-
cantly younger (61.1 ± 12.4 years) when compared with
anaemic Chinese (66.8 ± 11.9 years), Japanese/Koreans
(69.6 ± 12.8 years), and other ethnicities (62.4 ± 12.5 years),
respectively.
When Hb was modelled as quintiles (Table 3), the lowest
Hb quintile 5.0–11.3 g/dL was signiﬁcantly associated with
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Table 1 Baseline characteristics of the overall cohort and anaemic/non-anaemic subgroups in Asians with heart failure and reduced
ejection fraction
Variable Overall Non-anaemic Anaemic P-value
N (%) 3884 2278 (59) 1606 (41)
Demographics
Age in years ± SD 60 ± 13 58 ± 13 64 ± 13 <0.001
Female, n (%) 827 (21) 456 (20) 371 (23) 0.020
Geographical region, n (%) <0.001
North-east Asia 1456 (37) 952 (42) 504 (31)
South Asia 876 (23) 401 (18) 475 (30)
South-east Asia 1554 (40) 927 (41) 627 (39)
Ethnicity, n (%) <0.001
Chinese 1280 (33) 819 (36) 461 (29)
Indian 1019 (26) 465 (20) 554 (35)
Malay 585 (15) 353 (16) 232 (14)
Japanese or Korean 785 (20) 496 (22) 289 (18)
Other 215 (6) 145 (6) 70 (4)
Income region, n (%) <0.001
Low 1168 (30) 604 (26) 564 (35)
Middle 755 (19) 545 (24) 210 (13)
High 1963 (51) 1131 (50) 832 (52)
Medical history, n (%)
Ischaemic aetiology of HF 1867 (51) 964 (45) 903 (60) <0.001
NYHA Class III/IV 1353 (39) 785 (37) 568 (41) 0.033
Hypertension 2102 (54) 1164 (51) 938 (59) <0.001
Atrial ﬁbrillation/ﬂutter 770 (20) 473 (21) 297 (19) 0.085
Diabetes 1627 (42) 776 (34) 851 (53) <0.001
CKD 1710 (45) 801 (36) 909 (58) <0.001
Cancer 136 (4) 69 (3) 67 (4) 0.057
Previous stroke 276 (7) 154 (7) 122 (8) 0.308
COPD 365 (9) 224 (10) 141 (9) 0.276
PAVD 160 (4) 68 (3) 92 (6) <0.001
Peptic ulcer disease 127 (3) 75 (3) 52 (3) 0.936
Liver disease 149 (4) 85 (4) 64 (4) 0.674
Smoking history 1882 (49) 1183 (52) 699 (44) <0.001
Alcohol history 1210 (31) 800 (35) 410 (26) <0.001
Physical exam
SBP mmHg, mean ± SD 118 ± 20 118 ± 20 119 ± 20 0.662
DBP mmHg, mean ± SD 72 ± 13 74 ± 13 70 ± 12 <0.001
Peripheral oedema, n (%) 1022 (26) 558 (24) 464 (29) 0.002
Elevated JVP, n (%) 709 (18) 369 (16) 340 (21) <0.001
BMI kg/m2 24.7 ± 5.0 25.1 ± 5.3 24.1 ± 4.7 <0.001
Current medications, n (%)
ACEi/ARB 2746 (73) 1741 (79) 1005 (65) <0.001
Beta-blocker 2972 (79) 1801 (81) 1171 (76) <0.001
MRA 2146 (57) 1365 (62) 781 (51) <0.001
Diuretics 3059 (81) 1774 (80) 1285 (83) 0.019
Laboratory data
Hb (g/dL), mean ± SD 13.1 ± 2.1 14.5 ± 1.3 11.1 ± 1.2 <0.001
LVEF (%), median (IQR) 28.0 [21.5, 33.0] 27.0 [20.6, 33.0] 29.0 [23.0, 34.2] <0.001
eGFR mL/min/1.73 m2, median (IQR) 63.4 [45.1, 82.8] 68.5 [52.9, 85.8] 53.7 [34.7, 74.7] <0.001
Creatinine (mg/dL), median (IQR) 1.10 [0.90, 1.50] 1.04 [0.90, 1.30] 1.30 [0.92, 1.80] <0.001
Health-related QoL domaina
KCCQ clinical summary score 67.8 ± 0.5 63.1 ± 0.7 <0.001
KCCQ overall summary score 62.0 ± 0.5 58.1 ± 0.7 <0.001
KCCQ physical limitation score 67.1 ± 0.6 61.7 ± 0.8 <0.001
KCCQ quality of life score 53.3 ± 0.6 52.1 ± 0.7 0.243
KCCQ social limitation score 58.4 ± 0.8 53.0 ± 1.0 <0.001
KCCQ self-efﬁcacy score 63.8 ± 0.7 64.2 ± 0.8 0.694
KCCQ symptom burden score 69.5 ± 0.6 66.4 ± 0.8 0.003
KCCQ symptom frequency score 67.3 ± 0.7 62.2 ± 0.8 <0.001
KCCQ symptom stability score 64.1 ± 0.7 63.4 ± 0.9 0.540
KCCQ total symptom score 68.4 ± 0.6 64.3 ± 0.8 <0.001
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CKD, chronic kidney disease;
COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate; Hb, haemoglobin;
HF, heart failure; IQR, interquartile range; JVP, jugular venous pressure; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ven-
tricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PAVD, peripheral arterial vas-
cular disease; QoL, quality of life; SBP, systolic blood pressure; SD, standard error.
aHealth-related QoL domain scores adjusted for age, sex, ethnicity, income region, HF aetiology, LVEF, alcohol and smoking history, ACEi/
ARBs, MRAs, beta-blockers, diuretics, CKD, diabetes mellitus, atrial ﬁbrillation/ﬂutter, PAVD, liver disease, previous stroke, COPD, and can-
cer. Data presented as (adjusted) mean ± standard error of mean.
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higher hazard in the primary composite outcome, whereas
the two lowest Hb quintiles 5.0–11.3 and 11.4–12.6 g/dL
vs. the third Hb quintile 12.7–13.7 g/dL were associated
with higher hazards of 1 year mortality. Sex did not modify
the effect of Hb on both the primary composite and sec-
ondary outcomes tested.
Discussion
The results of this study show that anaemia is highly preva-
lent among Asian patients with HF, with signiﬁcant variation
among the different Asian ethnicities. Importantly, anaemia
Figure 1 Prevalence of anaemia in ASIAN-HF patients by (A) geographical region and by (B) ethnicity. (C) Kaplan–Meier curves of the primary compos-
ite outcome by ethnicity in anaemic and non-anaemic patients.
Table 2 Anaemia as a predictor of the primary composite endpoint of 1 year mortality and heart failure hospitalizations
Variable
Event rate Univariable analysis Multivariablea analysis
Overall Non-anaemic Anaemic Hazard ratio 95% CI P-value Hazard Ratio 95% CI P-value
Anaemia 1.35 1.17–1.56 <0.001 1.28 1.08–1.50 0.004
Stratiﬁed by ethnicity
Chinese 31.08 27.65 37.13 1.43 1.17–1.75 0.001 1.17 0.91–1.49 0.222
Indian 12.49 11.29 13.48 1.25 0.87–1.82 0.231 1.49 0.98–2.27 0.059
Malay 35.50 31.50 41.27 1.44 1.06–1.97 0.02 1.27 0.89–1.81 0.186
Japanese or Korean 11.85 8.09 18.56 2.46 1.61–3.76 <0.001 1.82 1.14–2.91 0.012
Other 16.79 15.38 20.00 1.68 0.65–4.36 0.285 1.75 0.57–5.38 0.325
Pinteraction 0.023
CI, conﬁdence interval.
The P-value for interaction is the interaction between ethnicity and anaemia for the association with the primary composite endpoint.
aAdjusted for age, sex, ethnicity, income region, heart failure aetiology, left ventricular ejection fraction, alcohol and smoking history, an-
giotensin-converting enzyme inhibitor/angiotensin II receptor blockers, mineralocorticoid receptor antagonists, beta-blockers, diuretics,
chronic kidney disease, diabetes mellitus, atrial ﬁbrillation/ﬂutter, peripheral artery vascular disease, liver disease, previous stroke, chronic
obstructive pulmonary disease, and cancer.
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severely impacts survival and QoL in Asian patients with HF.
Indian patients are especially prone to anaemia, which is
present in more than half of cases, whereas anaemia is re-
lated to the greatest risk of death or HF hospitalization in
Japanese/Korean patients with HF. These ﬁndings may carry
important implications for risk stratiﬁcation and management
of Asian patients with HF, especially given that iron deﬁciency
is now recognized to be a key and treatable cause of anaemia
in these patients.4,16,24–27
The prevalence of anaemia in HF has previously been
reported in European studies to range between 16% and
53%.3,5–8,12,13,28–36 Differences in characteristics of the study
populations could account for this wide range in prevalence.
For meaningful comparison with our results, we inspected
previous reports using the WHO deﬁnition of anaemia and
included patients with stable chronic heart failure with
reduced ejection fraction. Studies of acute decompensated
HF patients were excluded, as baseline Hb levels could be
falsely lowered by the acute ﬂuid overload status and
haemodilution. The overall prevalence of anaemia in our
Asian cohort (41%) was higher than that in similar studies
of predominantly White ethnicities (16–34%), despite
the younger age of our cohort (Supporting Information,
Table S2).
The prevalence of anaemia in the Indian subpopulation of
our study was particularly high, affecting >50% of Indian
patients with HF. A previous report on patients from
Singapore showed that Indian patients with HF had high
rates of iron deﬁciency.16 This suggests that iron deﬁciency
is a major contributing factor to the high prevalence of
anaemia among Indian patients with HF and that Indian
patients with HF may beneﬁt from contemporary treatment
for iron deﬁciency, including intravenous iron supplementa-
tion.24 Vegetarianism, black tea drinking, and potential
genetic factors have been explored as potential reasons
for the high prevalence of iron deﬁciency among Indians;11
however, this remains to be studied. Surprisingly, despite
the high prevalence of anaemia in Indian patients, anaemia
was not associated with outcomes in the Indian population.
This could in part be due to the younger age and better
renal function of anaemic Indians in ASIAN-HF, thus
representing a lower risk ethnic group in general compared
with the other Asian ethnic groups in ASIAN-HF. Accord-
ingly, outcomes among Indian patients were better com-
pared with other ethnic groups with anaemia (Table 2,
Figure 1C).
Data from the Japanese Cardiac Registry of Heart Fail-
ure in Cardiology (JCARE-CARD)15 showed a 57% preva-
lence of anaemia, compared with 37.5% in the Japanese
subpopulation of our ASIAN-HF cohort. We postulate that
this may be related to the lower mean eGFR in JCARE-
CARD (51.3 ± 25.3 mL/min/1.73 m2) compared with that
in the Japanese subpopulation of ASIAN-HF
(65.2 ± 29.3 mL/min/1.73 m2). This is further supported
by the signiﬁcant interaction we observed between CKD
and anaemia. Here, Japanese/Korean patients in particular
were at higher odds for having both CKD and anaemia,
suggesting that CKD is a major driving factor for the oc-
currence of anaemia in Japanese/Korean patients with
HF. This also holds true for Korean patients with HF. Pre-
vious studies from the Korean Heart Failure (KorHF) regis-
try reported higher rates of anaemia of 41.7%,37
Table 3 Effect of haemoglobin quintiles on outcomes
1 year all-cause mortality and HF hospitalizations
Variable (g/dL)
Univariable analysis Multivariablea analysis
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Q1 Hb 5.0–11.3 1.48 1.19–1.84 <0.001 1.43 1.13–1.82 0.003
Q2 Hb 11.4–12.6 1.21 0.96–1.52 0.105 1.24 0.97–1.58 0.086
Q3 Hb 12.7–13.7 1.00 Referent 1.00 Referent
Q4 Hb 13.8–14.9 1.05 0.83–1.33 0.705 1.00 0.78–1.29 0.985
Q5 Hb 15.0–20.8 0.97 0.76–1.24 0.82 0.99 0.76–1.29 0.936
1 year all-cause mortality
Univariable analysis Multivariablea analysis
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Q1 Hb 5.0–11.3 1.81 1.33–2.47 <0.001 1.80 1.27–2.53 0.001
Q2 Hb 11.4–12.6 1.35 0.97–1.87 0.076 1.50 1.06–2.14 0.022
Q3 Hb 12.7–13.7 1.00 Referent 1.00 Referent
Q4 Hb 13.8–14.9 1.04 0.73–1.48 0.829 1.11 0.76–1.63 0.578
Q5 Hb 15.0–20.8 1.13 0.80–1.59 0.498 1.38 0.94–2.03 0.096
CI, conﬁdence interval; Hb, haemoglobin; HF, heart failure.
aAdjusted for age, sex, ethnicity, income region, HF aetiology, left ventricular ejection fraction, alcohol and smoking history, angiotensin-
converting enzyme inhibitor/angiotensin II receptor blockers, mineralocorticoid receptor antagonists, beta-blockers, diuretics, chronic kid-
ney disease, diabetes mellitus, atrial ﬁbrillation/ﬂutter, peripheral artery vascular disease, liver disease, previous stroke, chronic obstructive
pulmonary disease, and cancer.
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compared with 35.5% in the Korean subpopulation of the
ASIAN-HF registry. In the KorHF registry, renal function was
poorer compared with the Korean patients from the
ASIAN-HF registry (creatinine level 1.5 ± 1.2 mg/dL vs.
1.3 ± 1.3 mg/dL). Taken together, these observations could
explain why anaemia was associated with the worst ad-
verse outcomes in Japanese/Korean patients, because the
anaemic status is closely related to CKD, which in itself
is associated with adverse outcomes.38
The clinical implications of this study are two-fold. The
high prevalence and potent clinical impact of anaemia among
Asian patients with HF suggest that screening for anaemia
would be important for risk stratiﬁcation in these patients.
We further highlight particular subgroups of patients who
may be targeted for screening (e.g. Indian ethnic group)
and identify CKD as a key driver of anaemia in speciﬁc sub-
groups (Japanese/Koreans). Whether treatment of anaemia
may improve outcomes among Asian patients with HF war-
rants further study in prospective clinical trials.
Study limitations
Iron indices were not available to enable determination of
cause of anaemia. Potential selection bias is evident in our
comparison of patients with and without Hb values and sug-
gests that we have included more severe cases of HF in these
analyses (Supporting Information, Table S1). While screening
logs were encouraged but not available from all sites, every
effort was made to ensure protocol adherence and standard-
ization including language translations speciﬁc to each region,
on-site investigator training, regular monitoring, and central-
ized database management. We further adjusted for periph-
eral oedema and raised JVP in an attempt to account for
the hemodilutional effect of ﬂuid overload.
Conclusions
This ﬁrst multi-ethnic ASIAN-HF study shows that anaemia is
highly prevalent in Asian patients with HF and adversely im-
pacts QoL and survival, with remarkable differences among
the different Asian ethnicities. The high prevalence and po-
tent clinical impact of anaemia among Asian patients with
HF suggest that anaemia may be an important therapeutic
target in these patients.
Acknowledgements
The contribution of all the site investigators and clinical
coordinators are acknowledged.
Conﬂict of interest
C.S.P.L. has received research support from Boston Scientiﬁc,
Medtronic, and Vifor Pharma and has consulted for Bayer,
Novartis, Takeda, Merck, Astra Zeneca, Janssen Research &
Development, LLC, and Menarini. She has served on the
Clinical Endpoint Committee for DC Devices.
A.M.R. has received research support from Boston
Scientiﬁc, Bayer, Astra Zeneca, Medtronic, Roche Diagnostics,
Abbott Laboratories, Thermo Fisher, and Critical Diagnostics
and has consulted for Bayer, Novartis, Merck, Astra Zeneca,
and Roche Diagnostics.
Funding
The ASIAN-HF study is supported by grants from the National
Medical Research Council of Singapore, the A*STAR Biomed-
ical Research Council ATTRaCT program, the Boston Scientiﬁc
Investigator Sponsored Research Program, and Bayer. C.S.P.L.
is supported by a Clinician Scientist Award from the National
Medical Research Council Singapore.
Supporting information
Additional Supporting Information may be found online in
the supporting information tab for this article.
Appendix S1. List of ASIAN-HF investigators.
Table S1. Baseline characteristics of patients with and with-
out Hb values.
Table S2. Comparison with other similar studies on anaemia
in heart failure.
References
1. Ponikowski P, Voors AA, Anker SD,
Bueno H, Cleland JG, Coats AJ, Falk V,
Gonzalez-Juanatey JR, Harjola VP,
Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske
B, Riley JP, Rosano GM, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer
P. 2016 ESC Guidelines for the Diagnosis
and Treatment of Acute and Chronic
576 V.J. Goh et al.
ESC Heart Failure 2018; 5: 570–578
DOI: 10.1002/ehf2.12279
Heart Failure. Rev Esp Cardiol (Engl Ed
2016; 69: 1167.
2. Ezekowitz JA, McAlister FA, Armstrong
PW. Anemia is common in heart failure
and is associated with poor outcomes:
insights from a cohort of 12 065 patients
with new-onset heart failure. Circulation
2003; 107: 223–225.
3. Anand IS, Kuskowski MA, Rector TS,
Florea VG, Glazer RD, Hester A, Chiang
YT, Aknay N, Maggioni AP, Opasich C,
Latini R, Cohn JN. Anemia and change
in hemoglobin over time related to mor-
tality and morbidity in patients with
chronic heart failure: results from Val-
HeFT. Circulation 2005; 112:
1121–1127.
4. Ebner N, Jankowska EA, Ponikowski P,
Lainscak M, Elsner S, Sliziuk V,
Steinbeck L, Kube J, Bekfani T,
Scherbakov N, Valentova M, Sandek A,
Doehner W, Springer J, Anker SD, von
Haehling S. The impact of iron deﬁ-
ciency and anaemia on exercise capacity
and outcomes in patients with chronic
heart failure. Results from the Studies
Investigating Co-morbidities Aggravat-
ing Heart Failure. Int J Cardiol 2016;
205: 6–12.
5. Jonsson A, Hallberg AC, Edner M, Lund
LH, Dahlstrom U. A comprehensive as-
sessment of the association between ane-
mia, clinical covariates and outcomes in
a population-wide heart failure registry.
Int J Cardiol 2016; 211: 124–131.
6. Adams KF Jr, Patterson JH, Oren RM,
Mehra MR, O’Connor CM, Pina IL, Miller
AB, Chiong JR, Dunlap SH, Cotts WG,
Felker GM, Schocken DD, Schwartz TA,
Ghali JK, Investigators S-HR. Prospective
assessment of the occurrence of anemia
in patients with heart failure: results from
the Study of Anemia in a Heart Failure
Population (STAMINA-HFP) Registry.
Am Heart J 2009; 157: 926–932.
7. Komajda M, Anker SD, Charlesworth A,
Okonko D,MetraM, Di Lenarda A, Remme
W, Moullet C, Swedberg K, Cleland JG,
Poole-Wilson PA. The impact of new onset
anaemia on morbidity and mortality in
chronic heart failure: results from COMET.
Eur Heart J 2006; 27: 1440–1446.
8. Cleland JG, Zhang J, Pellicori P, Dicken
B, Dierckx R, Shoaib A, Wong K, Rigby
A, Goode K, Clark AL. Prevalence and
outcomes of anemia and hematinic deﬁ-
ciencies in patients with chronic heart
failure. JAMA Cardiol 2016; 1: 539–547.
9. von Haehling S, Schefold JC, Hodoscek
LM, Doehner W, Mannaa M, Anker SD,
Lainscak M. Anaemia is an independent
predictor of death in patients hospital-
ized for acute heart failure. Clin Res
Cardiol 2010; 99: 107–113.
10. Triposkiadis F, Giamouzis G, Parissis J,
Starling RC, Boudoulas H, Skoularigis
J, Butler J, Filippatos G. Reframing the
association and signiﬁcance of co-
morbidities in heart failure. Eur J Heart
Fail 2016; 18: 744–758.
11. von Haehling S, Anker MS, Jankowska
EA, Ponikowski P, Anker SD. Anemia in
chronic heart failure: can we treat?
What to treat? Heart Fail Rev 2012; 17:
203–210.
12. von Haehling S, Gremmler U, KrummM,
Mibach F, Schon N, Taggeselle J, Dahm
JB, Angermann CE. Prevalence and clin-
ical impact of iron deﬁciency and anae-
mia among outpatients with chronic
heart failure: the PrEP Registry. Clin
Res Cardiol 2017; 106: 436–443.
13. Groenveld HF, Januzzi JL, Damman K,
van Wijngaarden J, Hillege HL, van
Veldhuisen DJ, van der Meer P. Anemia
and mortality in heart failure patients:
a systematic review and meta-analysis.
J Am Coll Cardiol 2008; 52: 818–827.
14. WHO. The Global Prevalence of Anaemia
in 2011. Geneva: World Health Organi-
zation; 2015.
15. Hamaguchi S, Tsuchihashi-Makaya M,
Kinugawa S, Yokota T, Takeshita A,
Yokoshiki H, Tsutsui H, Investigators
J-C. Anemia is an independent predictor
of long-term adverse outcomes in pa-
tients hospitalized with heart failure in
Japan. A report from the Japanese Car-
diac Registry of Heart Failure in Cardiol-
ogy (JCARE-CARD). Circ J 2009; 73:
1901–1908.
16. Yeo TJ, Yeo PS, Ching-Chiew Wong R,
Ong HY, Leong KT, Jaufeerally F, Sim D,
Santhanakrishnan R, Lim SL, M MYC,
Chai P, Low AF, Ling LH, Ng TP, Richards
AM, Lam CS. Iron deﬁciency in a multi-
ethnic Asian population with and without
heart failure: prevalence, clinical corre-
lates, functional signiﬁcance and progno-
sis. Eur J Heart Fail 2014; 16: 1125–1132.
17. Lam CS, Teng TK, Tay WT, Anand I,
Zhang S, Shimizu W, Narasimhan C, Park
SW, Yu CM, Ngarmukos T, Omar R, Reyes
EB, Siswanto BB, Hung CL, Ling LH, Yap J,
MacDonald M, Richards AM. Regional
and ethnic differences among patients
with heart failure in Asia: the Asian
sudden cardiac death in heart failure
registry. Eur Heart J 2016; 37: 3141–3153.
18. Lam CS, Anand I, Zhang S, Shimizu W,
Narasimhan C, Park SW, Yu CM,
Ngarmukos T, Omar R, Reyes EB,
Siswanto B, Ling LH, Richards AM.
Asian Sudden Cardiac Death in Heart
Failure (ASIAN-HF) registry. Eur J Heart
Fail 2013; 15: 928–936.
19. Nutritional anaemias. Report of a WHO
scientiﬁc group. World Health Organ
Tech Rep Ser 1968; 405: 5–37.
20. Schefold JC, Filippatos G, Hasenfuss G,
Anker SD, von Haehling S. Heart failure
and kidney dysfunction: epidemiology,
mechanisms and management. Nat Rev
Nephrol 2016; 12: 610–623.
21. Kosiborod M, Soto GE, Jones PG,
Krumholz HM, Weintraub WS,
Deedwania P, Spertus JA. Identifying
heart failure patients at high risk for
near-term cardiovascular events with se-
rial health status assessments. Circula-
tion 2007; 115: 1975–1981.
22. Luo N, T THK, Tay WT, Anand IS, Kraus
WE, Liew HB, Ling LH, O’Connor CM,
Pina IL, Mark Richards A, Shimizu W,
Whellan DJ, Yap J, Lam CSP, Mentz RJ,
ASIAN-HF, HF-ACTION investigators.
Multinational and multiethnic varia-
tions in health-related quality of life in
patients with chronic heart failure. Am
Heart J 2017; 191: 75–81.
23. Green CP, Porter CB, Bresnahan DR,
Spertus JA. Development and evalua-
tion of the Kansas City Cardiomyopathy
Questionnaire: a new health status mea-
sure for heart failure. J Am Coll Cardiol
2000; 35: 1245–1255.
24. Anker SD, Colet JC, Filippatos G,
Willenheimer R, Dickstein K, Drexler
H, Luscher TF, Mori C, von Eisenhart
Rothe B, Pocock S, Poole-Wilson PA,
Ponikowski P, Committees F-H, Investi-
gators. Rationale and design of Ferinject
assessment in patients with IRon
deﬁciency and chronic Heart Failure
(FAIR-HF) study: a randomized,
placebo-controlled study of intravenous
iron supplementation in patients with
and without anaemia. Eur J Heart Fail
2009; 11: 1084–1091.
25. Malyszko J, Anker SD. Iron therapy in
heart failure patients without anaemia:
possible implications for chronic kidney
disease patients. Clin Kidney J 2017;
10: i25–i31.
26. Anker SD, Kirwan BA, van Veldhuisen
DJ, Filippatos G, Comin-Colet J,
Ruschitzka F, Luscher TF, Arutyunov
GP, Motro M, Mori C, Roubert B, Pocock
SJ, Ponikowski P. Effects of ferric
carboxymaltose on hospitalisations and
mortality rates in iron-deﬁcient heart
failure patients: an individual patient
datameta-analysis. Eur J Heart Fail 2017.
27. Jankowska EA, Tkaczyszyn M, Suchocki
T, Drozd M, von Haehling S, Doehner
W, Banasiak W, Filippatos G, Anker SD,
Ponikowski P. Effects of intravenous iron
therapy in iron-deﬁcient patients with
systolic heart failure: a meta-analysis of
randomized controlled trials. Eur J Heart
Fail 2016; 18: 786–795.
28. Berry C, Poppe KK, Gamble GD, Earle
NJ, Ezekowitz JA, Squire IB, McMurray
JJ, McAlister FA, Komajda M, Swedberg
K, Maggioni AP, Ahmed A, Whalley GA,
Doughty RN, Tarantini L, Group MC.
Prognostic signiﬁcance of anaemia in
patients with heart failure with pre-
served and reduced ejection fraction: re-
sults from the MAGGIC individual
patient data meta-analysis. QJM 2016;
109: 377–382.
29. Hammadah M, Brennan ML, Wu Y,
Hazen SL, Tang WH. Usefulness of rela-
tive hypochromia in risk stratiﬁcation
for nonanemic patients with chronic
heart failure. Am J Cardiol 2016; 117:
1299–1304.
30. Mentz RJ, Greene SJ, Ambrosy AP,
Vaduganathan M, Subacius HP,
Swedberg K, Maggioni AP, Nodari S,
Ponikowski P, Anker SD, Butler J,
Gheorghiade M. Clinical proﬁle and
prognostic value of anemia at the time
of admission and discharge among pa-
tients hospitalized for heart failure with
Anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction 577
ESC Heart Failure 2018; 5: 570–578
DOI: 10.1002/ehf2.12279
reduced ejection fraction: ﬁndings from
the EVEREST trial. Circ Heart Fail
2014; 7: 401–408.
31. van der Meer P, Postmus D, Ponikowski
P, Cleland JG, O’Connor CM, Cotter G,
Metra M, Davison BA, Givertz MM,
Mansoor GA, Teerlink JR, Massie BM,
Hillege HL, Voors AA. The predictive
value of short-term changes in hemo-
globin concentration in patients pre-
senting with acute decompensated
heart failure. J Am Coll Cardiol 2013;
61: 1973–1981.
32. McCullough PA, Barnard D, Clare R, Ellis
SJ, Fleg JL, Fonarow GC, Franklin BA,
Kilpatrick RD, Kitzman DW, O’Connor
CM, Pina IL, Thadani U, Thohan V,
Whellan DJ, Investigators H-A. Anemia
and associated clinical outcomes in pa-
tients with heart failure due to reduced
left ventricular systolic function. Clin
Cardiol 2013; 36: 611–620.
33. Dunlay SM, Weston SA, Redﬁeld MM,
Killian JM, Roger VL. Anemia and heart
failure: a community study. Am J Med
2008; 121: 726–732.
34. O’Meara E, Clayton T, McEntegart MB,
McMurray JJ, Lang CC, Roger SD, Young
JB, Solomon SD, Granger CB, Ostergren
J, Olofsson B, Michelson EL, Pocock S,
Yusuf S, Swedberg K, Pfeffer MA, Com-
mittees C, Investigators. Clinical corre-
lates and consequences of anemia in a
broad spectrum of patients with heart
failure: results of the Candesartan in
Heart Failure: Assessment of Reduction
in Mortality and Morbidity (CHARM)
Program. Circulation 2006; 113:
986–994.
35. Go AS, Yang J, Ackerson LM, Lepper K,
Robbins S, Massie BM, Shlipak MG. He-
moglobin level, chronic kidney disease,
and the risks of death and hospitaliza-
tion in adults with chronic heart failure:
the Anemia in Chronic Heart Failure:
Outcomes and Resource Utilization
(ANCHOR) Study. Circulation 2006;
113: 2713–2723.
36. Horwich TB, Fonarow GC, Hamilton
MA, MacLellan WR, Borenstein J. Ane-
mia is associated with worse symptoms,
greater impairment in functional
capacity and a signiﬁcant increase in
mortality in patients with advanced
heart failure. J Am Coll Cardiol 2002;
39: 1780–1786.
37. Choi DJ, Han S, Jeon ES, Cho MC, Kim
JJ, Yoo BS, Shin MS, Seong IW, Ahn Y,
Kang SM, Kim YJ, Kim HS, Chae SC,
Oh BH, Lee MM, Ryu KH, Kor HFR.
Characteristics, outcomes and predictors
of long-term mortality for patients hos-
pitalized for acute heart failure: a report
from the Korean Heart Failure registry.
Korean Circ J 2011; 41: 363–371.
38. Damman K, Valente MA, Voors AA,
O’Connor CM, van Veldhuisen DJ,
Hillege HL. Renal impairment, worsen-
ing renal function, and outcome in pa-
tients with heart failure: an updated
meta-analysis. Eur Heart J 2014; 35:
455–469.
578 V.J. Goh et al.
ESC Heart Failure 2018; 5: 570–578
DOI: 10.1002/ehf2.12279
